Previous 10 | Next 10 |
Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarter LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2021 financial resul...
Company’s Technology Highlighted in Eleven Paper Presentations and One Electronic Poster LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions f...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the...
LENSAR, Inc. (LNSR) Q1 2021 Earnings Conference Call May 5, 2021 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chie Financial Officer Conference Call Participants Kevin Cai - Madison Avenue Presentation Operator Good morn...
LENSAR (LNSR): Q1 GAAP EPS of -$0.56 misses by $0.23.Revenue of $7.04M (+19.1% Y/Y) beats by $0.92M.Press Release For further details see: LENSAR EPS misses by $0.23, beats on revenue
First Quarter 2021 Procedure Volumes Increase 21.1% over First Quarter 2020 Cash and Cash Equivalents of $35.9 Million as of March 31, 2021 LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology compan...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2021 financial result...
LENSAR, Inc. (LNSR) Q4 2020 Earnings Conference Call March 10, 2021 8:30 AM ET Company Participants Lee Roth – Investor Relations-Burns McClellan Nick Curtis – Chief Executive Officer Tom Staab – Chief Financial Officer Conference Call Participants Richard Newitter ȁ...
LENSAR (LNSR): Q4 GAAP EPS of -$0.78 misses by $0.26.Revenue of $8.3M (-2.4% Y/Y) beats by $0.97M.Press Release For further details see: LENSAR EPS misses by $0.26, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global m...